NEW YORK, NY / ACCESSWIRE / November 13, 2018 / U.S. stocks closed down on Monday as oil prices continued to slide, raising concerns amongst investors. The Dow Jones Industrial Average plunged 2.32 percent to close at 25,387.18, while the S&P 500 Index shed 1.97 percent to close at 2,726.22. The Nasdaq Composite Index dropped 2.78 percent to close at 7,200.87.
According to Craig Callahan, Icon Advisors’ president and founder, the oil’s bear market
“These firms have hedged the price of oil, and projections for 2019 [earnings-per-share] growth are 25% for the sector,” compared to S&P 500’s growth of 9%, Callahan added.
MER Initiates Coverage on:
Bristol-Myers Squibb Company
Nektar Therapeutics' stock jumped 8.73% Monday, to close the day at $36.99. The stock recorded a trading volume of 6,219,847 shares, which was above its three months average volume of 2,220,939 shares. In the last year, Nektar Therapeutics' shares have traded in a range of 33.50 - 111.36. The share price has gained 10.42% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $46.75 is below its 200-day moving average of $58.41. Shares of the company are trading at a Price to Earnings ratio of 6.88. Shares of Nektar Therapeutics have fallen roughly 24.37 percent in the past month and are down 38.06 percent year-to-date.
Access MER's Nektar Therapeutics Research Report at:
On Monday, shares of Bristol-Myers Squibb recorded a trading volume of 6,259,780 shares, which was below the three months average volume of 7,213,656 shares. The stock ended the day 1.01% lower at $52.85. The share price has fallen 24.55% from its 52
Access MER's Bristol-Myers Squibb Company Research Report at:
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
MarketEdge has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of MarketEdgeReport.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. MarketEdgeReport.com is neither a registered
For any questions, inquiries, or comments reach out to us directly at:
MarketEdge Report, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.